Shanghai Fosun Pharma announced it has licensed US rights to a PD-1 candidate from its longstanding partner Henlius Biotech in an $840 million agreement. Read more here.
Beijing YishengBio will merge with SPAC vehicle Summit Healthcare Acquisition to list on Nasdaq. Sihuan Pharma subsidiary Xuanzhu Biopharm has filed for an IPO on the Shanghai STAR Exchange.
Merck, Novo, Sanofi and more pull off China growth thanks to price maneuvering But anxiety grows over outlook for biologics fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Fierce Pharma Asia—Ex-Genentech staffers IP theft; Lundbeck s Alzheimer s deal; China s oncology R&D rule fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.